Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843193 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
A Phase 2 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
- 20
- Study locations
NCT00843193 is a Phase 2 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 198 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00843193, a Phase 2 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
- 20
- Study locations
Study Summary
Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study
Conditions Studied
Interventions
- DRUG INTRAVENOUS GSK679586
- DRUG INTRAVENOUS PLACEBO
- DRUG FLUTICASONE PROPIONATE
Study Locations (20)
Other
- GSK Investigational Site - Lille
- GSK Investigational Site - Marseille
- GSK Investigational Site - Montpellier
- GSK Investigational Site - Nantes
- GSK Investigational Site - Saint-Pierre
- GSK Investigational Site - Strasbourg
- GSK Investigational Site - Tarbes
- GSK Investigational Site - Eindhoven
- GSK Investigational Site - Heerlen
- GSK Investigational Site - Hoorn
- GSK Investigational Site - Elverum
Oregon
- GSK Investigational Site - Medford
- GSK Investigational Site - Portland
Hesse
- GSK Investigational Site - Frankfurt am Main
- GSK Investigational Site - Gelnhausen
Pennsylvania
- GSK Investigational Site - Pittsburgh
South Carolina
- GSK Investigational Site - Orangeburg
Texas
- GSK Investigational Site - Boerne
Wisconsin
- GSK Investigational Site - Madison
Saxony-Anhalt
- GSK Investigational Site - Magdeburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2008-12-09 |
| Est. Completion | 2010-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00843193
The ClinicalTrials.gov registry entry for NCT00843193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which INTRAVENOUS GSK679586 is the first listed.
NCT00843193 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Oregon, Hesse.
Frequently Asked Questions
What is clinical trial NCT00843193 about?
NCT00843193 is a clinical study titled "Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma". Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study
What is the current status of trial NCT00843193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2008-12-09. Estimated completion is 2010-07-25.
What conditions does trial NCT00843193 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00843193?
The interventions under investigation include: INTRAVENOUS GSK679586 (DRUG), INTRAVENOUS PLACEBO (DRUG), FLUTICASONE PROPIONATE (DRUG).
Who is sponsoring clinical trial NCT00843193?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00843193 being conducted?
This trial has 20 study locations across Oregon, Pennsylvania, South Carolina, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.